We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic, Germany, Italy and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Synergy Auditorium 2
Silvari, Virginia
Linked to EAHP Statements
Section 1 – Introductory Statements and Governance: Statement 1.1
Section 2 – Selection, Procurement and Distribution: Statements 2.3, 2.7
Section 4 – Clinical Pharmacy Services: Statements 4.1, 4.2, 4.3, 4.4, 4.5
Section 5 – Patient Safety and Quality Assurance: Statements 5.1, 5.4, 5.5, 5.6
Agenda
– Tuesday, 23 March 2021: 18.30 – 19.15
Facilitator: Virginia Silvari
Presenter: Paul Wright
Topic: Minimising bleeding risk associated with anticoagulation use
Learning objectives of the session:
– List the reversible risk factors for bleeding in patients receiving a DOAC
– Determine the plans to reduce the risk of complications in patients receiving a DOAC by managing reversible risk factors for bleeding
ACPE UAN: 0475-0000-21-006-L04-P. A knowledge-based activity.
– Wednesday, 24 March 2021: 17.00 – 17.45
Facilitator: Virginia Silvari
Presenter: Patricia van den Bemt
Topic of the session: Antithrombotic stewardship: The proof of the pudding…
Learning objectives of the session:
– Explain how the establishment of an antithrombotic stewardship programme within the hospital can improve adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications.
– Disseminate the knowledge gained to both their peers and other healthcare professionals in their hospital.
ACPE UAN: 0475-0000-21-007-L04-P. A knowledge-based activity.
– Sunday, 28 March 2021: 10.00 – 10.30
Facilitator: Virginia Silvari
Presenters: Paul Wright; Patricia van den Bemt
Topic of the session: LIVE DISCUSSION with the faculty
ACPE UAN: 0475-0000-21-008-L04-P. A knowledge-based activity.
Abstract
Direct Oral Anticoagulants (DOACs) such as apixaban, edoxaban, rivaroxaban and dabigatran, have been recognized by evidence-based treatment guidelines as the first-line option for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) and the treatment of venous thromboembolism (VTE). More recently a low dose of rivaroxaban has been licensed for the prevention of atherothrombotic events in patients after acute coronary syndrome (ACS), in patients with coronary artery disease (CAD) or peripheral artery disease (PAD). Although DOACs are associated with a lower risk of intracranial haemorrhage or fatal bleeding compared to warfarin, there is still concern over their potential bleeding risk. Hospital Pharmacists can minimize the risk of bleeding of a patient on an anticoagulant by acting and modifying the reversible risk factors for bleeding such as hypertension, concomitant medications, alcohol misuse or patient’s poor adherence to anticoagulants (overdose). The Hospital Pharmacist can balance the antithrombotic benefit of the DOAC with its bleeding risk by recommending the appropriate dose of DOACs to physicians according to the patients’ characteristics (age, weight, renal functions). The Hospital Pharmacist as part of an antithrombotic stewardship programme needs to ensure adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications.
Learning objectives
The learning objectives of the seminar comprise the strategies the Hospital Pharmacist should apply to optimize anticoagulation use by appropriately modifying the reversible factors for bleeding.
After the Synergy session, participants should be able to:
• list the reversible risk factors for bleeding in patients receiving a DOAC;
• determine the plans to reduce the risk of complications in patients receiving a DOAC by managing reversible risk factors for bleeding;
• explain how the establishment of an antithrombotic stewardship programme within the hospital can improve adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications;
• disseminate the knowledge gained to both their peers and other healthcare professionals in their hospital.
ACPE information:
The Synergy Satellite is accredited by ACPE and in order to receive your ACPE accreditation points, what you have learnt during this session will be assessed.
During the session you will have to answer the self-assessment questions by scanning the QR code with your phone or clicking on the link available in the chat.
Educational need addressed
Hospital Pharmacists need to be aware of the appropriate use of DOACs to ensure the antithrombotic efficacy of the anticoagulants. At the same time, hospital pharmacists have to be conscious that anticoagulants, if used incorrectly, can cause bleeding and how, as part of an antithrombotic stewardship programme, they can prevent such complications by promoting adherence to anticoagulant guidelines.
Keywords: DOAC, antithrombotic, anticoagulant, stewardship, Low Molecular Weight Heparins (LMWH).
